| Bioactivity | Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct[1][2][3]. | ||||||||||||
| Invitro | Cilastatin (200 μg/mL; 24 hours; RPTECs) treatment protects against Vancomycin-induced proximal tubule apoptosis and increases cell viability, without compromising the antimicrobial effect of Vancomycin[2]. Apoptosis Analysis[2] Cell Line: | ||||||||||||
| Name | Cilastatin | ||||||||||||
| CAS | 82009-34-5 | ||||||||||||
| Formula | C16H26N2O5S | ||||||||||||
| Molar Mass | 358.45 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|